Abstract
Recently in Japan, the term "tonyobyo sei jinzobyo", the Japanese translation of "diabetic kidney disease", has been increasingly used in place of the term "tonyobyo sei jinsho", the Japanese translation of "diabetic nephropathy". Many international diabetes and nephrology guidelines have defined diabetic kidney disease as a condition caused by diabetes, typically presenting with albuminuria, similar to or identical to current and historical definitions for diabetic nephropathy. However, recent guidelines from the Japanese Society of Nephrology propose a broader disease concept for the term diabetic kidney disease, including patients without albuminuria. A rationale for proposing a broader disease concept for diabetic kidney disease may have come from changes in the kidney phenotype of patients with diabetes observed in recent years. Epidemiological studies have shown that an increasing proportion of patients with diabetes have reduced kidney function, while the prevalence of those with albuminuria appears to have decreased. However, these studies also suggested that the more advanced age of patients presenting with diabetes and increased use of renin-angiotensin system blockers may have contributed to this change in disease phenotype. We believe the principal rationale for the nomenclature change from diabetic nephropathy to diabetic kidney disease was to create a more easily understood, lay-language term for English speakers, rather than to create a term to encompass a broader population of diabetes with chronic kidney disease (CKD). Further discussion and international consensus are needed for the definition of diabetic kidney disease, to avoid ambiguity or possible confusion.
Similar content being viewed by others
References
Japanese Society of Nephrology. Evidence-based CKD Clinical Practice Guidelines 2018, Tokyo: Tokyo-igakusha; 2018
The 64th Annual Meeting of the Japanese Society of Nephrology. http://jsn64.umin.jp/
The 64th Annual Meeting of the Japan Diabetes Society. https://site.convention.co.jp/64jds/
The American Diabetes Association 81st Scientific Sessions. https://ada.scientificposters.com/epsSearchADA.cfm
Kidney Week 2021 of the American Society of Nephrology. https://www.asn-online.org/education/kidneyweek/2021/program-annual.aspx?day=Thursday
Friedman EA. Diabetic nephropathy: strategies in prevention and management. Kidney Int. 1982;21:780–91.
Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl. 2):64–78.
Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int. 1987;31:673–89.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.
Haneda M, Utsunomiya K, Koya D, et al. A new classification of diabetic nephropathy 2014: a report from joint committee on diabetic nephropathy. Diabetol Int. 2014;5:207–11.
Zins EI. Diabetic nephropathy. Am J Med Sci. 1949;218:408–18.
Wilson JL, Root HF, Marble A. Diabetic nephropathy; a clinical syndrome. N Engl J Med. 1951;245:513–7.
Goetz FC, Kjellstrand CM. The treatment of diabetic kidney disease. Diabetologia. 1979;17:267–81.
Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med. 1984;310:356–60.
Mogensen CE, Schmitz A, Christensen CK. Comparative renal pathophysiology relevant to IDDM and NIDDM patients. Diabetes Metab Rev. 1988;5:453–83.
KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49 (2):S1-S182
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64:510–33.
Diabetes Canada Clinical Practice Guidelines Expert Committee, McFarlane P, Cherney D, et al. Chronic kidney disease in diabetes. Can J Diabetes. 2018; 42(1): S201-S209
Liew A, Bavanandan S, Prasad N, et al. Asian Pacific society of nephrology clinical practice guideline on diabetic kidney disease. Nephrology. 2020;25(Suppl. 2):S12–45.
Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27:195–207.
Cohen Tervaert TW, Mooyaart AL, Amann K, et al. Pathological classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556–63.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020;98(4S):S1-S115
Hur KY, Moon MK, Park JS, et al. 2021 Clinical practice guidelines for diabetes mellitus of the Korean diabetes association. Diabetes Metab J. 2021;45:461–81.
National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management: 2021. https://www.nice.org.uk/guidance/ng203/resources/chronic-kidney-disease-assessment-and-management-pdf-66143713055173
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl. 1):S1–266.
Levey AS, Eckardt K-U, Dorman NM, et al. Nomenclature for kidney function and disease: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 2020;97:1117–29.
Anders H-J, Huber TB, Isermann B, et al. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14:361–77.
Alicic RZ, Johnson EJ, Tuttle KR. Diabetic kidney disease. In: Himmelfarb J, Ikizler TA, editors. Chronic kidney disease, dialysis, and transplantation. 4th ed. Philadelphia: Elsevier; 2019. p. 42–61.
Fornoni A, Nelson RG, Najafian B, Groop PH. Epidemiology of diabetic kidney disease. In: Yu ASL, Chertow GM, Luyckx V, Marsden PA, Skorecki K, Taal MW, editors. Brenner and rector’s the kidney. 11th ed. Elsevier; 2019. p. 1327–79.
Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8:2–7.
Yokoyama H, Araki S, Kawai K, et al. The prognosis of patients with type 2 diabetes and nonalbuminuric diabetic kidney disease is not always poor: implication of the effects of coexisting macrovascular complications (JDDM 54). Diabetes Care. 2020;43:1102–10.
Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316:602–10.
Tanaka N, Yamamoto Y, Yokoyama Y, et al. Temporal trends in the prevalence of albuminuria and reduced eGFR in Japanese patients with type 2 diabetes. Diabetol Int. 2019;10:279–87.
Kume S, Araki SI, Ugi S, et al. Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig. 2019;10:1032–40.
Shiraishi N, Kitamura K, Kohda Y, et al. Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population. Clin Exp Nephrol. 2014;18:461–8.
Glassock RJ, Delanaye P, Rule AD. Should the definition of CKD be changed to include age-adapted GFR criteria? YES Kidney Int. 2020;97:34–7.
Levey A, Inker LA, Coresh J. “Should the definition of CKD be changed to include age-adapted GFR criteria?” Con: the evaluation and management of CKD, not the definition, should be age-adapted. Kidney Int. 2020;97:37–40.
Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010;152:561–7.
Masakane I, Nakai S, Ogata S, et al. An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial. 2015;19:540–74.
Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020;75(suppl 1):6–7.
Abe M, Okada K, Maruyama N, et al. Comparison of clinical trajectories before initiation of renal replacement therapy between diabetic nephropathy and nephrosclerosis on the KDIGO Guidelines Heat Map. J Diabetes Res 2016;5374746
Anderson S, Rennke H, Brenner B. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993–2000.
Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005;54:2983–1987.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.
Koye DN, Magliano DJ, Reid CM, et al. Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis. 2018;72:653–66.
Yoshida Y, Kashiwabara K, Hirakawa Y, et al. Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diab Res Care. 2020;8: e000902.
Yamanouchi M, Furuichi K, Hoshino J, et al. Nonproteinuric versus proteinuric phenotypes in diabetic kidney disease: a propensity score-matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care. 2019;42:891–902.
Yamamoto Y, Hanai K, Mori T, et al. Kidney outcomes and all-cause mortality in people with type 2 diabetes exhibiting non-albuminuric kidney insufficiency. Diabetologia. 2022;65:234–45.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Babazono, T., Moriya, T. Lost in translation: assessing the nomenclature change for diabetic kidney disease in Japan. Diabetol Int 14, 319–326 (2023). https://doi.org/10.1007/s13340-023-00639-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13340-023-00639-9